NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUSES, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED UNDER SWEDISH LAW, IS PROHIBITED OR WOULD OTHERWISE BE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION, OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH MEASURES. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE FOR FURTHER INFORMATION.

The subscription period in the Rights Issue remains unchanged and runs from 15 September 2026 up to and including 29 September 2026.

Updated timetable for the Rights Issue

For further information, please contact:

Michael Colérus, Chief Financial Officer, telephone +46 70 341 34 72

This information was submitted for publication, through the agency of the contact persons set out above, on 15 September 2026 at 11.15 CEST.

Certified Adviser (CA):

DNB Carnegie Investment Bank AB (publ)

Telephone: +46 8 588 68 570,

E-mail: [email protected]

About SciBase:

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases

Important information:

The publication, release or distribution of this press release may in certain jurisdictions be subject to restrictions by law, and persons in the jurisdictions in which this press release has been made public or distributed should inform themselves about, and comply with, such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with the applicable rules in each jurisdiction.

The availability of the Rights Issue to holders not resident in Sweden may be affected by the legislation of the relevant jurisdiction in which they are located. Holders not resident in Sweden should inform themselves about, and comply with, all applicable laws and regulations.

This press release does not constitute an offer of, or an invitation to, acquire or subscribe for any securities in SciBase in any jurisdiction, either from SciBase or from anyone else. This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue. The Company has prepared and published an information document in respect of the Rights Issue. The information document is available on the Company's website (https://investors.scibase.se).

This press release does not identify, and does not purport to identify, any risks (direct or indirect) that may be associated with an investment in the Company. The information in this press release is intended only to describe the background to the Rights Issue and does not purport to be complete or exhaustive. No representation is made as to the accuracy or completeness of the information in this press release.

This press release does not constitute an offer of, or an invitation to, acquire or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended from time to time (the "Securities Act"), and may not be offered or sold in the United States absent registration, or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or any other jurisdiction in which such release, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would require registration, or measures other than those required under Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation.

Forward-looking statements

Matters discussed in this press release may contain forward-looking statements. Forward-looking statements are all statements that do not relate to historical facts and events, as well as statements relating to the future which, for example, contain expressions such as "anticipates", "intends", "may", "will", "should", "estimates", "believes", "could", "plans", "continues", "potential", "estimates", "forecasts", "known" or similar expressions. In particular, these statements relate to future results, financial position, cash flows, plans and expectations regarding the company's operations and management, future growth and profitability, as well as the general economic and regulatory environment and other circumstances affecting the company, many of which are in turn based on further assumptions, such as the absence of changes in existing political, legal, tax, market or economic conditions or in applicable laws (including, but not limited to, accounting principles, accounting methods and tax policies), which, individually or together, may be material to the company's results or its ability to conduct its operations. Although the Company considers that these assumptions were reasonable when they were made, they are by their nature subject to significant known and unknown risks, uncertainties, contingencies and other important factors that are difficult or impossible to predict and that may be beyond the Company's control. Such risks, uncertainties, contingencies and other material factors may cause actual events to differ materially from the expectations expressed or implied in such forward-looking statements. Prospective investors should therefore not place undue reliance on the forward-looking information contained herein, and prospective investors are strongly recommended to read those sections of the information document that contain a more detailed description of factors that may affect the Company's business and the market in which the Company operates. The information, opinions and forward-looking statements in this press release are valid only as at the date of this press release and may be subject to change without notice.

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUSES, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED UNDER SWEDISH LAW, IS PROHIBITED OR WOULD OTHERWISE BE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION, OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH MEASURES. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE FOR FURTHER INFORMATION.

In connection with the Rights Issue, the Company has prepared an information document (the "Information Document"). The Information Document is not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017, on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended (the "Prospectus Regulation") and has not been approved or reviewed by any regulatory authority in any jurisdiction. Nor does the Information Document constitute an exemption document in the form prescribed in accordance with the requirements of Annex IX to Article 1(4)(db) of the Prospectus Regulation.

SciBase today announces that the Information Document has been published and is available on the Company's website, http://www.scibase.com/, and will also be available on Bergs Securities' website, https://www.bergssecurities.se/.

Subscription forms will be available on the Company's website and will also be available on Bergs Securities' website, https://www.bergssecurities.se/.

Indicative timetable for the Rights Issue

Advisers

SciBase has engaged Bergs Securities and Birchtree Advisory as financial advisers and BAHR as legal adviser in connection with the Rights Issue. Bergs Securities is also acting as issuing agent in connection with the Rights Issue.

For further information, please contact:

Jesper Høiland, Chairman of the Board, telephone +45 612 207 30

Michael Colérus, Chief Financial Officer, telephone +46 70 341 34 72

Certified Adviser (CA):

DNB Carnegie Investment Bank AB (publ)

Telephone: +46 8 588 68 570,

E-mail: [email protected]

About SciBase:

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases

Important information:

The publication, release or distribution of this press release may in certain jurisdictions be subject to restrictions by law, and persons in the jurisdictions in which this press release has been made public or distributed should inform themselves about, and comply with, such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with the applicable rules in each jurisdiction.

The availability of the Rights Issue to holders not resident in Sweden may be affected by the legislation of the relevant jurisdiction in which they are located. Holders not resident in Sweden should inform themselves about, and comply with, all applicable laws and regulations.

This press release does not constitute an offer of, or an invitation to, acquire or subscribe for any securities in SciBase in any jurisdiction, either from SciBase or from anyone else. This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue. The Company has prepared and published an information document in respect of the Rights Issue. The information document is available on the Company's website (https://investors.scibase.se).

This press release does not identify, and does not purport to identify, any risks (direct or indirect) that may be associated with an investment in the Company. The information in this press release is intended only to describe the background to the Rights Issue and does not purport to be complete or exhaustive. No representation is made as to the accuracy or completeness of the information in this press release.

This press release does not constitute an offer of, or an invitation to, acquire or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended from time to time (the "Securities Act"), and may not be offered or sold in the United States absent registration, or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or any other jurisdiction in which such release, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would require registration, or measures other than those required under Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation.

Forward-looking statements

Matters discussed in this press release may contain forward-looking statements. Forward-looking statements are all statements that do not relate to historical facts and events, as well as statements relating to the future which, for example, contain expressions such as "anticipates", "intends", "may", "will", "should", "estimates", "believes", "could", "plans", "continues", "potential", "estimates", "forecasts", "known" or similar expressions. In particular, these statements relate to future results, financial position, cash flows, plans and expectations regarding the company's operations and management, future growth and profitability, as well as the general economic and regulatory environment and other circumstances affecting the company, many of which are in turn based on further assumptions, such as the absence of changes in existing political, legal, tax, market or economic conditions or in applicable laws (including, but not limited to, accounting principles, accounting methods and tax policies), which, individually or together, may be material to the company's results or its ability to conduct its operations. Although the Company considers that these assumptions were reasonable when they were made, they are by their nature subject to significant known and unknown risks, uncertainties, contingencies and other important factors that are difficult or impossible to predict and that may be beyond the Company's control. Such risks, uncertainties, contingencies and other material factors may cause actual events to differ materially from the expectations expressed or implied in such forward-looking statements. Prospective investors should therefore not place undue reliance on the forward-looking information contained herein, and prospective investors are strongly recommended to read those sections of the information document that contain a more detailed description of factors that may affect the Company's business and the market in which the Company operates. The information, opinions and forward-looking statements in this press release are valid only as at the date of this press release and may be subject to change without notice.

In 2025, SciBase entered into a collaboration and license agreement with Castle Biosciences (Nasdaq: CSTL), a US-based leader in molecular diagnostics. The first study under the collaboration project, which aims to predict relapses in atopic dermatitis (AD), is ongoing and this order is for both an acceleration of the initial clinical study as well as preparation for a second clinical study. Deliveries are expected to start in Q4 2026.

"The collaboration with Castle Biosciences is moving forward at a fast pace with rapid patient recruitment in our first joint study and this additional order signals the expansion of our collaboration," said Pia Renaudin, CEO of SciBase. "At SciBase we are very excited to, together with Castle Biosciences, help patients with skin barrier dysfunctions get access to more effective therapies."

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 03:00 PM CEST on September 8, 2026.

For additional information, please contact:

Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]

Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: [email protected]

About SciBase  
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company’s Certified Adviser is Carnegie Investment Bank AB (publ).  Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases  

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUSES, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED UNDER SWEDISH LAW, IS PROHIBITED OR WOULD OTHERWISE BE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION, OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH MEASURES. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE FOR FURTHER INFORMATION.

Summary of the Rights Issue

• The Board of Directors of SciBase has today, pursuant to the authorisation granted by the annual general meeting held on 19 May 2026, resolved to carry out the Rights Issue of shares of approximately SEK 57.5 million, before deduction of transaction costs.
• The net proceeds from the Rights Issue are intended to be used primarily to finance continued commercialisation activities with a focus on the US market.
• Shareholders who, on the record date of 10 September 2026, are registered in the share register maintained by Euroclear Sweden AB will receive one (1) subscription right for each share held. Eight (8) subscription rights entitle the holder to subscribe for three (3) new shares.
• The subscription price has been set at SEK 15 per share.
• The subscription period in the Rights Issue runs from and including 15 September 2026 up to and including 29 September 2026.
• Trading in subscription rights is expected to take place from and including 15 September 2026 up to and including 24 September 2026.
• The Rights Issue is covered by subscription undertakings in an aggregate amount of approximately SEK 33.3 million, corresponding to approximately 58 percent of the Rights Issue. In addition, Bergs Securities has entered into the Guarantee Intention of approximately SEK 24.2 million, corresponding to approximately 42 percent of the Rights Issue. Bergs Securities has entered into sub-guarantee agreements with a consortium of investors corresponding to the entire intended guarantee commitment. The subscription undertakings and the Guarantee Intention amount in aggregate to approximately SEK 57.5 million, corresponding to the entire Rights Issue.
• Of the subscription undertakings entered into, totalling approximately SEK 33.3 million, members of the Board of Directors and management of SciBase have undertaken to subscribe for shares in an aggregate amount of approximately SEK 1.2 million, corresponding to approximately 2 percent of the Rights Issue.
• In connection with the Rights Issue, the Company is preparing an information document. Further information about the Rights Issue and the Company will be provided in the information document, which is expected to be published on the Company's website on or around 14 September 2026.

"SciBase is in an exciting period, in which our melanoma diagnostics business is developing positively in the United States while we expect to reach an important commercial milestone in the form of reimbursement in the near future. The collaboration with Castle Biosciences creates significant potential within the diagnosis of atopic dermatitis and several other skin diseases. The collaboration covers the US market, which gives us the opportunity to address skin barrier diseases on our own in Europe and in further markets. Taken together, SciBase holds strong positions across several segments, which together create conditions for growth in both the short and the long term," says Pia Renaudin, CEO of SciBase.

"Under Pia's leadership, SciBase has established a strong position in the United States within melanoma diagnostics and has made significant progress within its other indication areas. The Company also has a well-functioning organisation that includes strong commercial teams in both the United States and Germany. The work to find a qualified successor is progressing well and our ambition is to present a new CEO in the coming months. The new CEO will have an important role in further developing SciBase from the strong position the company has established, with an undiminished focus on commercial development and cost control," says Jesper Høiland, Chairman of the Board of SciBase.

Background and reasons for the Rights Issue and use of proceeds

SciBase is a fast-growing medical technology company specialising in early detection and prevention within dermatology through the commercialisation of Nevisense, a patient-centric platform that combines AI and EIS technology (Electrical Impedance Spectroscopy) to increase diagnostic accuracy and thereby ensure early detection and prevention of skin diseases.

SciBase holds a strong position within melanoma diagnostics in Germany and an emerging position in the United States, where the Company is now focusing its resources. During the first half of 2026, SciBase's revenue grew by approximately 68 percent, to approximately SEK 29.6 million, driven by strong momentum in the United States. Within melanoma diagnostics, sales in the United States grew by approximately 79 percent, driven by strong sales of electrodes to both existing and new customers. The Company assesses that it is well positioned for continued growth in the United States, where access to reimbursement will be an important driver.

Alongside melanoma diagnostics in the United States, SciBase has for just over a year had an extensive collaboration with Castle Biosciences Inc ("Castle Biosciences") relating to the diagnosis of atopic dermatitis and a number of other skin diseases. The collaboration with Castle Biosciences is developing well and, during the most recent quarter, the first patients were enrolled in a study aimed at predicting flares in atopic dermatitis.

During the year, SciBase has devoted significant resources to strengthening its growth opportunities within both melanoma diagnostics and other indications. Extensive resources have been devoted to enabling reimbursement in the United States, where the Company assesses that an initial reimbursement decision will be received no later than early 2027. In order to meet increasing demand for Nevisense within both melanoma diagnostics and other indications, the Company has invested in increased production capacity, which has also increased the working capital tied up in the business. The measures taken strengthen SciBase's growth opportunities in both the short and the long term but have weighed on cash flow.

In order to capitalise on the strong momentum in the business and to finance the Company's operations over the coming year, the Company has resolved to carry out the Rights Issue.

The Rights Issue

Shareholders who, on the record date of 10 September 2026, are registered in SciBase's share register will receive one (1) subscription right for each share held in the Company. Eight (8) subscription rights entitle the holder to subscribe for three (3) new shares. The subscription price has been set at SEK 15 per share, meaning that SciBase will receive gross proceeds of approximately SEK 57.5 million before deduction of transaction costs, provided that the Rights Issue is fully subscribed. In addition, investors are offered the opportunity to apply for subscription of shares in the Rights Issue without the support of subscription rights.

The subscription period in the Rights Issue is expected to run from and including 15 September 2026 up to and including 29 September 2026. The last day of trading in SciBase's shares including the right to receive subscription rights in the Rights Issue is 8 September 2026. The shares will be traded excluding the right to receive subscription rights in the Rights Issue from and including 9 September 2026. Trading in subscription rights is expected to take place on Nasdaq First North Growth Market during the period from and including 15 September 2026 up to and including 24 September 2026, and trading in BTA (paid subscribed shares) will take place on Nasdaq First North Growth Market during the period from and including 15 September 2026 until on or around 16 October 2026 (following registration of the Rights Issue with the Swedish Companies Registration Office).

In the event that not all shares in the Rights Issue are subscribed for with the support of subscription rights, the Board of Directors shall, within the maximum amount of the Rights Issue, resolve on the allotment of shares subscribed for without the support of subscription rights in accordance with the following allotment principles:

1. Firstly, allotment shall be made to those who have subscribed for shares with the support of subscription rights, irrespective of whether the subscriber was a shareholder on the record date or not, and, in the event of oversubscription, in proportion to the number of subscription rights that each party has exercised for subscription of shares and, to the extent this is not possible, by the drawing of lots.
2. Secondly, allotment shall be made to other subscribers who have subscribed for shares without the support of subscription rights and, in the event of oversubscription, in proportion to the number of shares subscribed for and, to the extent this is not possible, by the drawing of lots.
3. Thirdly and lastly, any remaining shares shall be allotted to any parties that have guaranteed the Rights Issue, pro rata in relation to any guarantee undertakings provided and in accordance with any guarantee agreements entered into.

If the Rights Issue is fully subscribed, a maximum of 3,834,487 new shares may be issued, corresponding to a maximum dilution of approximately 27 percent of the total number of shares and votes in the Company. Shareholders have the opportunity to compensate themselves financially for this dilution effect by selling the subscription rights they receive.

Indicative timetable for the Rights Issue

Number of shares and share capital

The Rights Issue entails that the share capital may increase by a maximum of SEK 19,172,435, from SEK 51,126,500 to SEK 70,298,935, and that the number of shares may increase by a maximum of 3,834,487 shares, from 10,225,300 shares to 14,059,787 shares, corresponding to a maximum dilution of approximately 27 percent of the total number of shares and votes in the Company following registration of the Rights Issue with the Swedish Companies Registration Office.

Subscription undertakings and Guarantee Intention

Several existing shareholders, including Ribbskottet AB, Castle Biosciences Inc, Haga Gruppen Holding AB, Life Science Invest Fund 1 ApS and Praktikerinvest AB, as well as members of the Company's Board of Directors and management, have entered into subscription undertakings in an aggregate amount of approximately SEK 33.3 million, corresponding to approximately 58 percent of the Rights Issue. Castle Biosciences' undertaking is conditional upon Castle Biosciences' holding in the Company, following the Rights Issue, being below 20 percent of the total number of outstanding shares and votes in the Company.

Furthermore, Bergs Securities has entered into the Guarantee Intention of approximately SEK 24.2 million, corresponding to approximately 42 percent of the Rights Issue. Bergs Securities may, up until the expiry of the subscription period, fulfil the Guarantee Intention, whereupon a binding guarantee commitment arises. In support of the Guarantee Intention, Bergs Securities has entered into sub-guarantee agreements, corresponding to the entire intended guarantee commitment, with a number of investors against pre-agreed compensation.

In the event that the guarantee commitment under the Guarantee Intention is fulfilled by Bergs Securities, guarantee compensation will be payable amounting to 10 percent of the guaranteed amount in cash or, alternatively, 12 percent of the guaranteed amount in newly issued shares in the Company. If the guarantee compensation is settled in newly issued shares, these will be issued at a subscription price corresponding to the subscription price per share in the Rights Issue. The Board of Directors intends to resolve on a directed issue of shares if the guarantee compensation is to be paid in the form of shares, pursuant to the same authorisation as is used for the Rights Issue. In aggregate, a maximum of 193,669 shares may be issued in the form of guarantee compensation, meaning that the share capital may increase by a further maximum of SEK 968,345 and result in additional dilution of approximately 1.4 percent. The compensation has been determined following arm's length negotiations and is deemed to reflect prevailing market conditions. No compensation is payable to those who have provided subscription undertakings, with or without the support of pre-emptive rights. No undertakings or intentions in connection with the Rights Issue are, or will be, secured by bank guarantee, blocked funds, pledge or similar arrangements.

Information document

In connection with the Rights Issue, the Company is preparing an information document. Further information about the Rights Issue and the Company will be provided in the information document, which is expected to be published on the Company's website on or around 14 September 2026.

The Swedish Foreign Direct Investment Screening Act

The Company assesses that it conducts activities worthy of protection pursuant to the Swedish Act (2023:560) on the Screening of Foreign Direct Investments (the "FDI Act"). In accordance with the FDI Act, the Company is required to inform prospective investors that the Company's operations may fall within the scope of the regulation and that the investment may be subject to a notification requirement. Where an investment is subject to a notification requirement, it must, before it is completed, be notified to the Swedish Inspectorate of Strategic Products ("ISP"). An investment may be subject to a notification requirement if (i) the investor, any person in its ownership structure or any person on whose behalf the investor is acting would, following completion of the investment, hold votes corresponding to or exceeding any of the thresholds of 10, 20, 30, 50, 65 or 90 percent of the total number of votes in the Company, (ii) the investor acquires the Company through the investment and the investor, any person in its ownership structure or any person on whose behalf the investor is acting would, directly or indirectly, have at its disposal 10 percent or more of the total number of votes in the Company, and (iii) the investor, any person in its ownership structure or any person on whose behalf the investor is acting would, through the investment, obtain direct or indirect influence over the management of the Company. The investor may be subject to an administrative fine if an investment that is subject to a notification requirement is completed before ISP has either (i) decided to take no action in respect of the notification or (ii) approved the investment. Each shareholder should consult an independent legal adviser regarding the potential application of the FDI Act to the Rights Issue for that individual shareholder.

Advisers

SciBase has engaged Bergs Securities and Birchtree Advisory as financial advisers and BAHR as legal adviser in connection with the Rights Issue. Bergs Securities is also acting as issuing agent in connection with the Rights Issue.

For further information, please contact:

Jesper Høiland, Chairman of the Board, telephone +45 612 207 30

Michael Colérus, Chief Financial Officer, telephone +46 70 341 34 72

This information is information that SciBase Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on 3 September 2026 at 8.45 CEST.

Certified Adviser (CA):

DNB Carnegie Investment Bank AB (publ) Telephone: +46 8 588 68 570, E-mail: [email protected]

About SciBase:

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ).  Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases

Important information:

The publication, release or distribution of this press release may in certain jurisdictions be subject to restrictions by law, and persons in the jurisdictions in which this press release has been made public or distributed should inform themselves about, and comply with, such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with the applicable rules in each jurisdiction.

The availability of the Rights Issue to holders not resident in Sweden may be affected by the legislation of the relevant jurisdiction in which they are located. Holders not resident in Sweden should inform themselves about, and comply with, all applicable laws and regulations.

This press release does not constitute an offer of, or an invitation to, acquire or subscribe for any securities in SciBase in any jurisdiction, either from SciBase or from anyone else. This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue. The Company will prepare and publish an information document in respect of the Rights Issue. The information document will be made available on the Company's website (https://investors.scibase.se).

This press release does not identify, and does not purport to identify, any risks (direct or indirect) that may be associated with an investment in the Company. The information in this press release is intended only to describe the background to the Rights Issue and does not purport to be complete or exhaustive. No representation is made as to the accuracy or completeness of the information in this press release.

This press release does not constitute an offer of, or an invitation to, acquire or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended from time to time (the "Securities Act"), and may not be offered or sold in the United States absent registration, or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or any other jurisdiction in which such release, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would require registration, or measures other than those required under Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation.

Forward-looking statements

Matters discussed in this press release may contain forward-looking statements. Forward-looking statements are all statements that do not relate to historical facts and events, as well as statements relating to the future which, for example, contain expressions such as "anticipates", "intends", "may", "will", "should", "estimates", "believes", "could", "plans", "continues", "potential", "estimates", "forecasts", "known" or similar expressions. In particular, these statements relate to future results, financial position, cash flows, plans and expectations regarding the company's operations and management, future growth and profitability, as well as the general economic and regulatory environment and other circumstances affecting the company, many of which are in turn based on further assumptions, such as the absence of changes in existing political, legal, tax, market or economic conditions or in applicable laws (including, but not limited to, accounting principles, accounting methods and tax policies), which, individually or together, may be material to the company's results or its ability to conduct its operations. Although the Company considers that these assumptions were reasonable when they were made, they are by their nature subject to significant known and unknown risks, uncertainties, contingencies and other important factors that are difficult or impossible to predict and that may be beyond the Company's control. Such risks, uncertainties, contingencies and other material factors may cause actual events to differ materially from the expectations expressed or implied in such forward-looking statements. Prospective investors should therefore not place undue reliance on the forward-looking information contained herein, and prospective investors are strongly recommended to read those sections of the information document that contain a more detailed description of factors that may affect the Company's business and the market in which the Company operates. The information, opinions and forward-looking statements in this press release are valid only as at the date of this press release and may be subject to change without notice.

The second quarter in figures

• Net sales were TSEK 15,308 (8,791), +74%, cleared for currency effects +84%.
• The loss after tax was TSEK 28,893 (22,911).
• The loss per share was SEK 2.83 (6.77).
• The cash flow from current operations was negative in the amount of TSEK 33,095 (20,466).
• The gross margin was 52,6% (66.2%).
• Electrode sales volume increased by 118% and was 40,144 (18,398) units. Repeat sales of electrodes to existing customers increased by 75% (incl deliveries to Castle).

The first half-year in figures

• Net sales were TSEK 29,586 (17,648), +68%, cleared for currency effects +79%.
• The loss after tax was TSEK 53,383 (43,592).
• The loss per share was SEK 5.80 (13.69).
• The cash flow from current operations was negative in the amount of TSEK 59,669 (46,467).
• The gross margin was 51.0% (68.4%).
• Electrode sales volume increased by 95% and was 70,556 (36,268) units. Repeat sales of electrodes to existing customers increased by 74% (incl deliveries to Castle).

Important events during the quarter

• Overall sales increased by 74% (+84%, before currency effects). Sales in Germany within the skin cancer segment increased by 18% vs Q2-25 (increased by 18% in local currency).  Sales in the US skin cancer market increased by 80% (88% in local currency) while the sales within the skin barrier segment increased by 3,231%.
• The gross margin was negatively affected in the quarter by the currency development (negative impact of over 5%), continued deliveries of products to Castle Biosciences for clinical studies, increased price on gold and continued investments to ramp up production. Cleared for currency effects and Castle deliveries, the margin was around 70%.

• SciBase collaboration with Castle has now entered the next phase as the first patient has been included in a new study to assess flare prediction in Atopic Dermatitis.

• SciBase performed a reverse split 1:100.

• A new study was published in the peer-reviewed journal Allergy  demonstrating that results from Nevisense measurements obtained shortly after birth identified children who subsequentially developed atopic dermatitis (AD).

• A new study was presented demonstrating that Nevisense (EIS) can successfully detect and quantify age-related changes in the skin barrier.

• A study was presented showing that Nevisense can identify damage to the skin barrier from surfactants in household cleaning products.

• SciBase reaches milestone with over 400,000 tests sold globally.

• The 2026 AGM was held on May 19^th.

Important events after the end of the     period

• SciBase submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking to expand the U.S. indication for Nevisense to include the assessment of Non-Melanoma Skin Cancers (keratinocyte skin cancers).

• SciBase announced changes in senior management.

Financial overview   

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on August 19, 2026.

This interim report report has not been subject to review by the Company’s auditors

Contact person:

Michael Colérus, CFO, +46 70 341 34 72, e-mail: [email protected]

For additional information, please contact:

Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]

Certified Advisor (CA):



DNB Carnegie Investment Bank AB (publ)



Tel: +46 8 588 68 570



Email: [email protected]

About SciBase and Nevisense

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company’s Certified Adviser is DNB Carnegie Investment Bank AB (publ).  Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases

The change in leadership does not alter SciBase strategy or overarching goals. All plans remain firmly in place, with a focus on the U.S. market and securing reimbursement for the use of Nevisense in skin cancer diagnostics. A top priority is also the collaboration with Castle Biosciences, which will lead to an expanded offering and increased use of Nevisense. SciBase has an experienced, strong, and well-composed management team that collectively drives the company's growth agenda, providing a stable foundation as the Board recruits a new CEO. The U.S. organization, led by Leda Beaty, is well-equipped to continue driving development in the American market.

"Pia Renaudin has played a crucial role during her years as CEO in shaping the strategy, structure, and organization to ensure SciBase can fully capitalize on the potential of Nevisense," says Jesper Hoiland, Chairman of the Board of SciBase. "Under her leadership, the company has strengthened its position in the U.S. market and built an organization with the right expertise to broaden the use of Nevisense and drive development forward in the U.S. On behalf of the Board and myself, I would like to extend our deepest gratitude to Pia for her contributions and driven leadership. We wish her the best in her new role."

"SciBase is now entering a new phase where the strategy and foundation is in place, and I feel this is the right time to hand over responsibility to a new CEO. I am incredibly proud of the fantastic development the company has achieved in recent years. The U.S. organization is doing an outstanding job, and an experienced management team is in place to guide the company through the next phase. Against this backdrop, it feels like the right moment for me to move on and take on a new challenge. I would like to extend my warmest thanks to Jesper and the Board, the management team, and all employees for their incredible efforts in striving to improve cancer diagnostics and save patients' lives," says Pia Renaudin.

The Board has now initiated a recruitment process to find Pia Renaudin's successor.

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 09.00 CET on July 28 2026.

For further information please contact:

Pia Renaudin, CEO,

Phone. +46732069802

E-mail: [email protected]  

Certified Advisor (CA):

DNB Carnegie Investment Bank AB (publ)

Tel: +46 8 588 68 570

E-mail: [email protected]

About SciBase and Nevisense
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ).  Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases

--------------------------------------------------------------------------------------

Nevisense is currently the only FDA-approved AI-driven technology in dermatology for the assessment and early detection of melanoma. If cleared, the expanded indication would extend the clinical utility of the existing Nevisense platform to include non-melanoma skin cancers, representing a significant expansion of its addressable U.S. market.

Non-Melanoma Skin Cancer Burden

More than 5.4^1,2) million cases of basal cell carcinoma and squamous cell carcinoma are diagnosed annually in the United States, making keratinocyte skin cancer the most common form of cancer. Delayed diagnosis can lead to, in the case of squamous cell carcinoma, metastatic disease, highlighting the need for objective technologies that support earlier clinical assessment and more informed biopsy decisions.

The submitted 510(k) premarket notification seeks to expand Nevisense's indication to include lesions with characteristics of keratinocyte skin cancer. In Europe, Nevisense is already CE marked for use in both melanoma and keratinocyte skin cancer, making the U.S. submission an important milestone in SciBase's strategy to broaden the clinical application of its technology.

"This submission represents an important milestone for SciBase and our strategy to expand the clinical applications of Nevisense in the United States," said Pia Renaudin, Chief Executive Officer of SciBase. "Keratinocyte skin cancer is estimated to be the most common form of cancer, and we believe Nevisense has the potential to provide dermatologists with objective decision support across an even broader range of suspicious skin lesions. Expanding Nevisense beyond melanoma represents an important step toward supporting clinicians across the broader spectrum of skin cancers encountered in daily dermatology practice. We look forward to working closely with the FDA throughout the review process."

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.30 CET on July 1, 2026.

For further information please contact:

Pia Renaudin, CEO,

Phone. +46732069802

E-mail: [email protected]  

Certified Advisor (CA):

DNB Carnegie Investment Bank AB (publ)

Tel: +46 8 588 68 570

E-mail: [email protected]

About SciBase and Nevisense
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ).  Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases

--------------------------------------------------------------------------------------

References

1. American Cancer Society. Cancer Facts & Figures 2025. (Melanoma incidence and ranking in the United States.)
2. American Academy of Dermatology. Approximately 5.4 million cases of basal cell carcinoma and squamous cell carcinoma are diagnosed annually in the United States.

The primary objective of the multicenter prospective clinical study is to assess the prediction of flares in atopic dermatitis (AD). This milestone marks a significant step forward in understanding and managing this chronic, inflammatory skin condition, which affects millions of people worldwide.

The study, titled DETECT-AD, the first study through the collaboration with Castle Biosciences, will investigate SciBase method of Electrical Impedance Spectroscopy (EIS) ability to predict the onset of flares in patients with atopic dermatitis. By identifying early signs, the research aims to enable proactive interventions, improve patient quality of life, and reduce the burden of unpredictable flare-ups.

Atopic dermatitis is characterized by periods of remission and flare-ups, which can significantly impact patients' daily lives. Current treatment approaches are often reactive, addressing symptoms only after they appear. This study seeks to shift the paradigm toward proactive, personalized care, empowering patients and healthcare providers with actionable insights.

"The enrollment of the first patient is an exciting milestone in our mission to transform the management of atopic dermatitis. By predicting flares before they occur, we hope to offer patients greater control over their condition and improve their overall well-being", said Pia Renaudin, CEO of SciBase.,

For further information please contact:

Pia Renaudin, CEO,

Phone. +46732069802

E-mail: [email protected]  

Certified Advisor (CA):

DNB Carnegie Investment Bank AB (publ)

Tel: +46 8 588 68 570

E-mail: [email protected]

About SciBase and Nevisense
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ).  Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases

--------------------------------------------------------------------------------------

The study, which was previously orally presented at the AAAAI conference in Philadelphia February 27 - March 2, was conducted by researchers at the Icahn School of Medicine at Mount Sinai and assessed neonatal skin barrier integrity using Nevisense within the first days of life. Infants who developed atopic dermatitis during their first year had significantly higher neonatal measurements than those who remained disease-free, suggesting that Nevisense may serve as a non-invasive early biomarker of skin barrier dysfunction associated with future atopic dermatitis risk.

Atopic dermatitis affects approximately 15-20% of children worldwide and is one of the most common chronic inflammatory skin diseases of infancy and childhood.¹⁾ It is often the first manifestation of the "atopic march," a progression that may later include food allergies, asthma, and allergic rhinitis. The ability to identify skin barrier dysfunction before the onset of clinical symptoms could enable earlier risk assessment, support future prevention strategies, and improve patient stratification in both clinical practice and research

Conclusion from the study was "Higher EIS scores, suggestive of impaired skin barrier, within the first week of life were significantly associated with development of AD in the first year of life."

"The publication of these findings in a leading peer-reviewed allergy journal represents an important milestone", said Pia Renaudin, CEO of SciBase. "These results support the potential of Nevisense not only as a technology for assessing skin barrier integrity, but also as an early biomarker that may help identify infants at increased risk of developing atopic dermatitis before clinical symptoms emerge."

The publication adds to a growing body of evidence supporting Nevisense as a non-invasive technology platform for assessing skin barrier integrity and dysfunction. Together with previous studies, these findings further strengthen the potential role of Nevisense in earlier risk assessment, prevention strategies, disease monitoring, and future therapeutic development in atopic dermatitis and other skin barrier disorders.

The authors conclude that reliable, non-invasive technologies for assessing skin barrier integrity remain an important unmet need. Their findings demonstrate the potential of Nevisense to detect early skin barrier dysfunction and identify infants at elevated risk for atopic dermatitis before disease onset.

The article titled" Elevated Neonatal Electrical Impedance Spectroscopy Measurements Are Associated With Atopic Dermatitis in High-Risk Infants" is published in the journal Allergy and can be found through this link: https://onlinelibrary.wiley.com/doi/10.1111/all.70402,

For further information please contact:

Pia Renaudin, CEO,

Phone. +46732069802

E-mail: [email protected]  

Certified Advisor (CA):

DNB Carnegie Investment Bank AB (publ)

Tel: +46 8 588 68 570

E-mail: [email protected]

About SciBase and Nevisense
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ).  Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases

--------------------------------------------------------------------------------------